Literature DB >> 10861454

A tumor suppressor locus in familial and sporadic chordoma maps to 1p36.

M Miozzo1, L Dalprà, P Riva, M Volontà, F Macciardi, S Pericotti, M G Tibiletti, M Cerati, K Rohde, L Larizza, A M Fuhrman Conti.   

Abstract

Previous cytogenetic/FISH data have demonstrated 1p36 deletions in a relapsing familial clivus chordoma developed by a patient who has 2 daughters, respectively affected with childhood astrocytoma and clivus chordoma. Using an approach that combined the LOH (loss of heterozygosity) study of the father chordoma and the daughter astrocytoma and a segregation analysis from parents to sibs using 17 CA-repeats spanning 1p36.32-1p36.11, we mapped the cancer susceptibility locus in this family to the 1p36 region. The LOH and haplotype information was elaborated using a pairwise linkage analysis that gave a maximum lod score of 1.2. Additional LOH data relating to 6 sporadic chordomas allowed us to define an SRO (the smallest region of overlapping loss) of about 25 cM from D1S2845 (1p36.31) to D1S2728 (1p36.13). Our overall findings converge on mapping to 1p36 a tumor-suppressor gene involved in familial and sporadic chordoma. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10861454

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Clinical findings in families with chordoma with and without T gene duplications and in patients with sporadic chordoma reported to the Surveillance, Epidemiology, and End Results program.

Authors:  Dilys M Parry; Mary L McMaster; Norbert J Liebsch; Nicholas J Patronas; Martha M Quezado; Deborah Zametkin; Xiaohong R Yang; Alisa M Goldstein
Journal:  J Neurosurg       Date:  2020-06-19       Impact factor: 5.115

Review 2.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

3.  1p36.32 rearrangements and the role of PI-PLC η2 in nervous tumours.

Authors:  Vincenza Rita Lo Vasco
Journal:  J Neurooncol       Date:  2010-09-29       Impact factor: 4.130

4.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

5.  Familial chordoma: A case report and review of the literature.

Authors:  K E Wang; Zhen Wu; Kaibing Tian; Liang Wang; Shuyu Hao; Liwei Zhang; Junting Zhang
Journal:  Oncol Lett       Date:  2015-09-09       Impact factor: 2.967

6.  Update on the cytogenetics and molecular genetics of chordoma.

Authors:  Lidia Larizza; Pietro Mortini; Paola Riva
Journal:  Hered Cancer Clin Pract       Date:  2005-02-15       Impact factor: 2.857

7.  Case report: familial gastric cancer and chordoma in the same family.

Authors:  Walter Weber; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2005-05-15       Impact factor: 2.857

8.  Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.

Authors:  Sangyeul Han; Carolyn Polizzano; Gunnlaugur P Nielsen; Francis J Hornicek; Andrew E Rosenberg; Vijaya Ramesh
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

9.  Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.

Authors:  Mauro Longoni; Francesca Orzan; Michela Stroppi; Nicola Boari; Pietro Mortini; Paola Riva
Journal:  Neuro Oncol       Date:  2007-12-19       Impact factor: 12.300

Review 10.  The molecular aspects of chordoma.

Authors:  Sukru Gulluoglu; Ozlem Turksoy; Aysegul Kuskucu; Ugur Ture; Omer Faruk Bayrak
Journal:  Neurosurg Rev       Date:  2015-09-12       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.